Spero suspends SPR720 development after Phase 2a miss; cuts workforce 39%, extends cash runway to mid-2026

Spero Therapeutics, Inc.

SPR720 Phase 2a interim analysis did not meet primary endpoint; 3 cases of reversible grade 3 hepatotoxicity at 1,000 mg dose.
Company restructuring with ~39% workforce reduction; expects ~$1.1M in cash restructuring charges.
Unaudited Q3 2024 cash ~$76.3M; cash runway extended into mid-2026.
Tebipenem HBr PIVOT-PO Phase 3 trial on track for enrollment completion in 2H 2025.
IND cleared for SPR206 Phase 2 trial in HABP/VABP, contingent on non-dilutive funding.

item 2.02 item 2.05 item 7.01 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.